Related Experiment Video
Updated: Feb 9, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13
Zhong Chen1,2, Dayong Wu3, Jennifer M Thomas-Ahner4
1Department of Pathology, Duke University School of Medicine, Durham, NC 27710.
Abstract:
The constitutively active androgen receptor (AR) splice variant 7 (AR-V7) plays an important role in the progression of castration-resistant prostate cancer (CRPC). Although biomarker studies established the role of AR-V7 in resistance to AR-targeting therapies, how AR-V7 mediates genomic functions in CRPC remains largely unknown. Using a ChIP-exo approach, we show AR-V7 binds to distinct genomic regions and recognizes a full-length androgen-responsive element in CRPC cells and patient tissues. Remarkably, we find dramatic differences in AR-V7 cistromes across diverse CRPC cells and patient tissues, regulating different target gene sets involved in CRPC progression. Surprisingly, we discover that HoxB13 is universally required for and colocalizes with AR-V7 binding to open chromatin across CRPC genomes. HoxB13 pioneers AR-V7 binding through direct physical interaction, and collaborates with AR-V7 to up-regulate target oncogenes. Transcriptional coregulation by HoxB13 and AR-V7 was further supported by their coexpression in tumors and circulating tumor cells from CRPC patients. Importantly, HoxB13 silencing significantly decreases CRPC growth through inhibition of AR-V7 oncogenic function. These results identify HoxB13 as a pivotal upstream regulator of AR-V7-driven transcriptomes that are often cell context-dependent in CRPC, suggesting that HoxB13 may serve as a therapeutic target for AR-V7-driven prostate tumors.
Insights
Androgen receptor splice variant 7 (AR-V7) drives castration-resistant prostate cancer (CRPC). HoxB13 protein is essential for AR-V7’s genomic function and promotes CRPC growth, suggesting HoxB13 as a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- The androgen receptor splice variant 7 (AR-V7) is crucial for castration-resistant prostate cancer (CRPC) progression.
- The precise genomic mechanisms by which AR-V7 drives CRPC remain largely unelucidated.
Purpose of the Study:
- To investigate the genomic binding patterns and functional role of AR-V7 in CRPC.
- To identify key regulators of AR-V7's transcriptional activity in CRPC.
Main Methods:
- Chromatin immunoprecipitation followed by exonuclease digestion (ChIP-exo) was employed to map AR-V7 binding sites.
- CRPC cell lines and patient tissues were analyzed for AR-V7 and HoxB13 interactions.
- CRPC cell growth was assessed following HoxB13 silencing.
Main Results:
- AR-V7 binds to distinct genomic regions, recognizing androgen-responsive elements in CRPC cells and tissues.
- AR-V7 cistromes exhibit significant variability across different CRPC contexts, affecting diverse gene sets.
- HoxB13 is universally required for AR-V7 binding, physically interacts with AR-V7, and co-regulates oncogene expression.
- HoxB13 silencing inhibits AR-V7's oncogenic function and reduces CRPC growth.
Conclusions:
- HoxB13 acts as a critical upstream regulator of AR-V7-driven transcriptomes in a context-dependent manner in CRPC.
- HoxB13 is a potential therapeutic target for AR-V7-positive prostate tumors.
Related Concept Videos
Treatment Resistant Cancers
Cell Diversity
Multicellular...
Diversity of Archaea II
Diversity of Protists I
Diversity of Protists II
Diversity of Archaea I

